Physician profile
Robert A Pollack
NPI 1497725089
$13,642.11
in general payments reported to CMS, 2019-2025
36 companies · $482 in 2025
The $482 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,633 · 2020: $1,312 · 2021: $2,493 · 2022: $2,689 · 2023: $2,677 · 2024: $2,357 · 2025: $482.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,516.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,516.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,746.62 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,060.45 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $1,846.75 | 2019-2025 | Entyvio, Eohilia |
| Janssen Biotech, INC. | $1,391.25 | 2019-2025 | Stelara, Tremfya, Simponi |
| Celgene Corporation | $583.08 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $428.84 | 2021-2023 | |
| Pfizer INC. | $419.29 | 2019-2025 | |
| Ardelyx, INC. | $353.50 | 2022-2024 | Ibsrela |
| Ferring Pharmaceuticals INC. | $285.81 | 2019-2024 | Rebyota |
| Intercept Pharmaceuticals, INC. | $250.33 | 2019-2024 | Ocaliva |
| Gilead Sciences, INC. | $238.52 | 2019-2025 | |
| Qol Medical, LLC | $218.86 | 2019-2024 | Sucraid |
| Merck Sharp & Dohme LLC | $216.97 | 2019-2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $216.54 | 2020-2024 | Linzess |
| Boston Scientific Corporation | $142.10 | 2019-2025 | Apollo Esg Nxt System |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $138.24 | 2019-2020 | |
| Lilly USA, LLC | $118.42 | 2023-2025 | Omvoh |
| Daiichi Sankyo INC. | $115.19 | 2019-2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $102.27 | 2023-2025 | Dupixent |
| Genzyme Corporation | $101.14 | 2023-2024 | |
| Amgen INC. | $91.65 | 2020-2021 | |
| Fresenius Kabi USA, LLC | $68.30 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.93 | 2023 | Cyltezo |
| Romark Laboratories, Lc | $56.39 | 2019-2020 | |
| Vivus LLC | $50.97 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $49.53 | 2023-2024 | Voquezna |
| Madrigal Pharmaceuticals | $44.80 | 2024-2025 | Rezdiffra, Resmetirom |
| Shionogi INC | $39.01 | 2019 | |
| Tms Neurohealth Centers INC. | $38.66 | 2025 | Tms Neurohealth Centers INC. |
| Braintree Laboratories, INC. | $36.84 | 2020-2022 | |
| Aimmune Therapeutics, INC. | $34.35 | 2024 | |
| Redhill Biopharma INC. | $27.20 | 2021-2022 | |
| Angiodynamics, INC. | $24.08 | 2023 | Auryon Laser System 100-120 Vac |
| Intra-Sana Laboratories | $18.60 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Echosens North America, INC. | $13.52 | 2024 | Fibroscan |
| Evoke Pharma, INC. | $12.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pollack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.